| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Neurology (Dr. DeAngelis), Radiation Oncology (Dr. Yahalom), and Medical Imaging (Dr. Krol), and the Divisions of Ophthalmology (Dr. Heinemann) and Biostatistics (C. Cirrincione and Dr. Thaler), Memorial Sloan-Kettering Cancer Center, New York, NY.
Primary central nervous system lymphoma (PCNSL), an uncommon tumor, is occurring with increasing frequency. Conventional therapy with corticosteroids and cranial radiotherapy (RT) usually gives a dramatic initial response, but median survival is only 10 to 18 months. Chemotherapy is more successful in comparable systemic lymphoma and has been employed for PCNSL at relapse, causing remission but not cure. Between June 1985 and June 1988, we prospectively staged 32 patients with PCNSL at Memorial Sloan-Kettering Cancer Center and treated 28 on a new protocol that combined chemotherapy and radiotherapy at diagnosis. None had occult systemic lymphoma, but 19% had ocular and 69% had definite or probable leptomeningeal lymphoma. There were no complications in 19 stereotactic biopsies, but 4/10 patients who had a complete resection suffered a severe postoperative deficit. Four patients received RT alone, and 28 received chemotherapy and cranial RT, 17 of whom (group A) received a combination regimen using pre-RT systemic (1 g/m2) and intra-Ommaya methotrexate (MTX), 4,000 cGy whole-brain RT with a 1,440 cGy boost, and 2 courses of post-RT high-dose cytosine arabinoside; 5 other patients received an identical regimen but with a decreased dose of MTX (200 mg/m2). Sixty-three percent of assessable patients had a response to MTX independent of corticosteroid and prior to RT. Eighteen of 26 (69%) assessable patients who received combined therapy are alive with a median follow-up of 25.4 months. Twelve of 16 (75%) assessable group A patients are alive in the same period. Chemotherapy-related toxicity was minimal, and no late toxicities have occurred to date. A vigorous multimodality approach to PCNSL was well tolerated, and survival is markedly improved over conventional therapy.
Address correspondence and reprint requests to Dr. L.M. DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue New York, NY 10021.
Dr. DeAngelis is a recipient of an American Cancer Society Clinical Oncology Career Development Award.
Presented in part at the 40th annual meeting of the American Academy of Neurology, Cincinnati, OH, April 1988.
Received April 21, 1989. Accepted for publication in final form June 13, 1989.
This article has been cited by other articles:
|
|
 |
|
  A. F. Hottinger, L. M. DeAngelis, J. Yahalom, and L. E. Abrey Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma Neurology, September 11, 2007; 69(11): 1178 - 1182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Abrey, L. Ben-Porat, K. S. Panageas, J. Yahalom, B. Berkey, W. Curran, C. Schultz, S. Leibel, D. Nelson, M. Mehta, et al. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model J. Clin. Oncol., December 20, 2006; 24(36): 5711 - 5715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Batchelor and J. S. Loeffler Primary CNS Lymphoma J. Clin. Oncol., March 10, 2006; 24(8): 1281 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. T. Batchelor, B. R. Buchbinder, and N. L. Harris Case 1-2005 - A 35-Year-Old Woman with Difficulty Walking, Headache, and Nausea N. Engl. J. Med., January 13, 2005; 352(2): 185 - 194. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Ishikawa, M. Hasegawa, Y. Tamaki, K. Hayakawa, T. Akimoto, H. Sakurai, N. Mitsuhashi, H. Niibe, M. Tamura, and T. Nakano Comparable Outcomes of Radiation Therapy without High-dose Methotrexate for Patients with Primary Central Nervous System Lymphoma Jpn. J. Clin. Oncol., September 1, 2003; 33(9): 443 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J.M. Ferreri, J.-Y. Blay, M. Reni, F. Pasini, M. Spina, A. Ambrosetti, A. Calderoni, A. Rossi, V. Vavassori, A. Conconi, et al. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience J. Clin. Oncol., January 15, 2003; 21(2): 266 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A multicenter study of treatment of primary CNS lymphoma Neurology, May 28, 2002; 58(10): 1513 - 1520.
|
|
|
|
 |
|
 A. J. M. Ferreri, J.-Y. Blay, M. Reni, F. Pasini, A. Gubkin, U. Tirelli, A. Calderoni, E. Zucca, S. Cortelazzo, C. Chassagne, et al. Relevance of intraocular involvement in the management of primary central nervous system lymphomas Ann. Onc., April 1, 2002; 13(4): 531 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Gleissner, J. Siehl, A. Korfel, R. Reinhardt, and E. Thiel CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes Neurology, February 12, 2002; 58(3): 390 - 396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Soussain, F. Suzan, K. Hoang-Xuan, N. Cassoux, V. Levy, N. Azar, C. Belanger, E. Achour, V. Ribrag, S. Gerber, et al. Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular Lymphoma J. Clin. Oncol., February 1, 2001; 19(3): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. P. O'Neill, C.-H. Wang, J. R. O'Fallon, J. P. Colgan, J. D. Earle, R. L. Krigel, L. D. Brown, and W. J. McGinnis The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: Cognitive function and performance status Neuro-oncol, July 1, 1999; 1(3): 196 - 203. [Abstract] [PDF]
|
|
|
|
 |
|
 L. M DeANGELIS Primary central nervous system lymphoma J. Neurol. Neurosurg. Psychiatry, June 1, 1999; 66(6): 699 - 701. [Full Text]
|
|
|
|
 |
|
 M. D de Smet, V. S. Vancs, D. Kohler, D. Solomon, and C. C. Chan Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma Br. J. Ophthalmol., April 1, 1999; 83(4): 448 - 451. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
